Ari Polachek1, Suzanne Li2, Vinod Chandran3, Dafna D Gladman4. 1. University of Toronto, Toronto Western Hospital, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto, Ontario, Canada. 2. Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and University Health Network, Toronto, Ontario, Canada. 3. University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, and University Health Network, Toronto, Ontario, Canada. 4. University of Toronto, Krembil Research Institute, Center for Prognosis Studies in the Rheumatic Diseases, and Toronto Western Hospital, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: To evaluate the incidence, prevalence, characteristics, disease associations, risk factors, and outcome of clinical enthesitis in patients with psoriatic arthritis (PsA). METHODS: The study included patients with PsA followed prospectively. Enthesitis was defined as the presence of at least 1 tender enthesis at 1 of the 18 entheseal sites of the Spondyloarthritis Research Consortium of Canada enthesitis index. RESULTS: Between 2008 and 2014, 281 of 803 patients had enthesitis, providing a prevalence of 35%. A total of 192 patients developed enthesitis during the course of followup, with an annual incidence of 0.9%. Most of the patients had 1 (48.4%) or 2 (32.2%) tender entheseal sites, and the mean ± SD number of sites per visit was 2.03 ± 1.6. The 3 most common sites were at the insertions of the Achilles tendon, plantar fascia on the calcaneus, and the lateral epicondyles (24.2%, 20.8%, and 17.2%, respectively). More active disease (higher actively inflamed joint count, tenosynovitis, and dactylitis), more pain, and less clinical damage were associated with enthesitis. Higher body mass index, more actively inflamed joints, and younger age were risk factors for developing this condition. Enthesitis resolved in most patients without changing treatment. CONCLUSION: Clinical enthesitis is common, with a period prevalence of 35% of PsA patients. It usually involves only 1 or 2 sites simultaneously. The most common tender sites are at the insertions of the Achilles tendon, plantar fascia, and the lateral epicondyles. More active disease and more pain are associated with enthesitis.
OBJECTIVE: To evaluate the incidence, prevalence, characteristics, disease associations, risk factors, and outcome of clinical enthesitis in patients with psoriatic arthritis (PsA). METHODS: The study included patients with PsA followed prospectively. Enthesitis was defined as the presence of at least 1 tender enthesis at 1 of the 18 entheseal sites of the Spondyloarthritis Research Consortium of Canada enthesitis index. RESULTS: Between 2008 and 2014, 281 of 803 patients had enthesitis, providing a prevalence of 35%. A total of 192 patients developed enthesitis during the course of followup, with an annual incidence of 0.9%. Most of the patients had 1 (48.4%) or 2 (32.2%) tender entheseal sites, and the mean ± SD number of sites per visit was 2.03 ± 1.6. The 3 most common sites were at the insertions of the Achilles tendon, plantar fascia on the calcaneus, and the lateral epicondyles (24.2%, 20.8%, and 17.2%, respectively). More active disease (higher actively inflamed joint count, tenosynovitis, and dactylitis), more pain, and less clinical damage were associated with enthesitis. Higher body mass index, more actively inflamed joints, and younger age were risk factors for developing this condition. Enthesitis resolved in most patients without changing treatment. CONCLUSION: Clinical enthesitis is common, with a period prevalence of 35% of PsA patients. It usually involves only 1 or 2 sites simultaneously. The most common tender sites are at the insertions of the Achilles tendon, plantar fascia, and the lateral epicondyles. More active disease and more pain are associated with enthesitis.
Authors: Lu Yang; Melania H Fanok; Aranzazu Mediero-Munoz; Laura K Fogli; Carmen Corciulo; Shahla Abdollahi; Bruce N Cronstein; Jose U Scher; Sergei B Koralov Journal: Arthritis Rheumatol Date: 2018-04-18 Impact factor: 10.995
Authors: Rebecca Haberman; Lourdes M Perez-Chada; Joseph F Merola; Jose Scher; Alexis Ogdie; Soumya M Reddy Journal: Curr Rheumatol Rep Date: 2018-10-26 Impact factor: 4.592